Last updated on July 2019

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 Followed by PNEUMOVAX 23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018/PNEU-WAY)


Brief description of study

This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in pneumococcal vaccine-nave adults infected with HIV and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX23 when administered 8 weeks after receipt of either V114 or Prevnar 13.

Clinical Study Identifier: NCT03480802

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.